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Testicular cancer is a curable cancer which mostly affects men
between 20 and 35 years of age. Major progress was achieved with
the introduction of cisplatin into combination chemotherapy regi-
mens, yielding cure rates of 70–85% in patients with metastatic
disease (Einhorn, 1990; Bokemeyer, 1998). Since most patients
with testicular cancer are of a young age, the impact of therapy on
sexual function and fertility has become increasingly important.
Testicular cancer patients may have a reduced spermatogenesis
(‘hypospermia’) at diagnosis (Hendry et al, 1983; Berthelsen and
Skakkebaek, 1984; Cassileth and Steinfeld, 1987; Moynihan,
1987; Nijman et al, 1987; Fossa et al, 1988; Sleijfer et al, 1995)
and after orchidectomy (Lampe et al, 1997), and only between
22 and 63% of patients fulfil the definition of normospermia at
diagnosis (Hendry et al, 1983; Fossa et al, 1985; Nijman et al,
1987; Lampe et al, 1997). Three disease-associated conditions,
local structural abnormalities detected by biopsy of the contra-
lateral testis, the presence of sperm antibodies and endocrine
factors, may be responsible (Berthelsen and Skakkebaek, 1984;
Guazzieri et al, 1985). Treatment-related factors have additionally
been identified, for example decrease of testosterone levels after
orchidectomy. However, no strong correlation was demonstrable
between testosterone serum concentration and erection (Buena
et al, 1993; van Basten et al, 1995). Leydig cell function as well
as testosterone production can be affected by radio- and
chemotherapy (von Eschenbach, 1980; Aass et al, 1991).
Irradiation may cause small vessels disease and peripheral
neuropathy resulting in erectile dysfunction (Fossa et al, 1980;
von Eschenbach, 1980; Tomic et al, 1983; Goldstein et al, 1984;
Fossa et al, 1986). The possible organic–biologic effects of
chemotherapy itself are also complex, including temporary
reduction of testosterone levels, hyperprolactinaemia, induction of
vascular damage and peripheral neuropathy (El-Beheiry et al,
1988; Aass et al, 1991; van Basten et al, 1997a). Retroperitoneal
lymph node dissection (RPLND) may cause permanent dry ejacu-
lation due to the surgical interruption of retroperitoneal sympa-
thetic nerves (Drasga et al, 1983). The different effects of
treatment on sexual functioning make their evaluation a complex
problem, particularly in patients treated with more than one thera-
peutic modality. Large differences regarding the frequencies of
sexual dysfunctions and the influence of different treatments are
reported in the literature (Rieker et al, 1985, 1989; Schover and
Eschenbach, 1985; Schover et al, 1986; Gritz et al, 1989; Tinkler
et al, 1992; Aass et al, 1993; Bloom et al, 1993; Arai et al, 1997;
Jonker-Pool et al, 1997). The aim of the present descriptive
investigation was to evaluate the incidence of long-term effects
on sexuality and try to identify treatment-related differences.
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Summary This retrospective study evaluates the types and incidences of sexual disturbances and fertility distress in patients cured from
testicular cancer and examines whether there is an effect resulting from different treatment modalities. A self-reported questionnaire was sent
to 124 randomly selected patients who were treated at Hanover University Medical School between 1970 and 1993. Ninety-eight patients
were included in the study, representing a response rate of 78%. All patients had been in complete remission (CR) for at least 24 months. The
median age at diagnosis was 28 years (range 17–44). The median follow-up at the time of study was 12.0 years (range 2.8–25.6). Twenty
patients (20%) had been treated for seminomatous and 78 patients (80%) for non-seminomatous germ cell tumours. Treatment included
surveillance (7%), primary retroperitoneal lymph node dissection (RPLND) (13%), chemotherapy (CT) (33%), CT + secondary resection of
residual retroperitoneal tumour mass (SRRTM) (43%) and infradiaphragmatic radiotherapy (4%). Patients receiving two treatment modalities
(CT+SRRTM) reported more frequent an unfulfilled wish for children. Inability of ejaculation was clearly associated with RPLND and SRRTM.
Subjective aspects of sexuality, like loss of sexual drive and reduced erectile potential, occurred only in a minority of patients after treatment.
No abnormalities were observed concerning the course of pregnancies of partners. In conclusion, sexual dysfunction and infertility are
common long-lasting sequelae in testicular cancer survivors affecting approximately 20% of patients. The relative risk for infertility appeared
to be elevated for patients treated with the combination of CT+SRRTM. Twenty-one of 40 patients were able to fulfil their wish for children, and
no congenital abnormalities were observed in these children.
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The medical records of testicular cancer patients treated at the
Department of Hematology/Oncology of Hanover University
Medical School between 1970 and 1993 were reviewed. A written
self-report questionnaire concerning sexual function was sent to
124 patients who were randomly selected and who had had no
evidence of disease for more than 2 years. Since no adequate
validated questionnaire was available at the begining of study it
was designed in corporation with the Department of Medical
Psychology and the Department of Gynaecology at Hanover
University Medical School. The questionnaire consisted of 41
issues related to fertility and sexual function before and after treat-
ment, e.g. decrease in sexual response (libido, sexual drive, erec-
tion, orgasm), ejaculation function, changes in sexual activity and
satisfaction, as well as items concerning child-bearing, course of
pregnancy and state of health of offspring, and demographics. For
the variable ‘intensity of sexual life’ (including the ‘intensity of
orgasm’ (0 = no orgasm, 1 = pronounced decrease, 2 = slighty
decreased, 3 = normal feeling) and the ‘frequency of sexual inter-
course’ (0 = never, 1 = rarely, 2 = frequently, 3 = very often))
answers were ranked on a four-point scale (score). Medical infor-
mation was obtained from the patients’ records. Clinical staging of
patients was available according to the Lugano Classification
(Cavalli et al, 1980). Patients were divided into four subgroups,
according to the following treatment modalities: (1) orchidectomy
and surveillance, SV; (2) primary retroperitoneal lymph node
dissection, RPLND; (3) cisplatin-based combination chemo-
therapy, CT; (4) combination of chemotherapy and secondary
surgery, CT+SRRTM. Four patients who had received infradi-
aphragmatic radiotherapy (RT) were not considered in the analysis
comparing different treatment modalities due to the small number
of patients available. The applied chemotherapy regimens are
summarized in Table 1 (Williams et al, 1987; Loehrer et al, 1988;
Einhorn, 1990; Harstrick et al, 1991; Schmoll et al, 1993;
Bokemeyer et al, 1996). The differences in sexual dysfunctions
between the treatment subgroups were tested with the c2-test or
Fisher’s exact test for categorial variables, and Kruskal–Wallis test
and the Wilcoxon test for continuous variables. Differences were
considered to be statistically significant at P-values less than 0.05.
RESULTS
Patients’ characteristics
Of 124 evaluable patients from our registry, 26 patients (21%) did
not return the questionnaire. Thus, aspects of sexuality and fertility
were assessed in 98 men at a median follow-up period of 12.0
years after the diagnosis of testicular cancer (range 2.8–25.6).
Twenty patients (20%) had been treated for seminomatous and 78
(80%) for non-seminomatous germ cell tumours. Treatment
included RPLND alone in 13 patients (13%), radiotherapy (RT)
alone in four patients (4%), CT alone in 32 patients (33%), and 42
patients underwent CT+SRRTM (43%). Seven patients underwent
orchidectomy alone and surveillance for stage I disease (7%).
Patients’ characteristics are outlined in detail in Table 2.
Pretreatment fertility status and fatherhood after
treatment
Thirty-nine (40%) patients had fathered 53 children before the
diagnosis of testicular cancer (Table 2). All 53 children with a
median age of 14.5 years (range 12.2–17.3) at the time of this
investigation were reported to have developed normally. No preg-
nancies occurred during any cancer treatment.
Twenty-one of 40 (53%) patients who reported a wish for child-
ren had fathered children at a median time of 54 months after the
end of treatment (3–108 months). Additionally, two women
interrupted gravidity at 8 months and at 2 years after the end of
cancer treatment of their male partner. Nineteen of 40 (48%)
patients who tried to obtain conception, have been unsuccessful
after a median duration of nearly 5 years. Pathological semen
analysis (‘azoospermia’/< 1 ´ 106 ml–1) could be identified in
15 patients (79%) and permanent dry ejaculation in one patient
(5%). Two patients were found to suffer from psychosocial
distress causing reduced erectile potential (11%). In one case the
spouse did not want to attain pregnancy (5%).
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Table 1 Type of chemotherapy (No. of patients = 74)
PEB cisplatin (20 mg m–2; days 1–5) 40 (67%)
etoposide (100 mg m–2; days 1–5)
bleomycin (30 mg; days 2, 9, 16)
PVB cisplatin (20 mg m–2; days 1–5) 8 (11%)
vinblastine (0.2 mg kg–1; days 1, 2)
bleomycin (30 mg; days 2, 9, 16)
PEI cisplatin (20 mg m–2; days 1–5) 5 (7%)
etoposide (75 mg m–2; days 1–5)
ifosfamide (1.2 g m–2; days 1–5)
PEBOI cisplatin (50 mg m–2; days 1–3) 8 (11%)
etoposide (170 mg m–2; days 1–3)
bleomycin (15 mg m–3; days 1, 8, 15, 22)
vincristine (2 mg; days 1, 8, 15, 22)
ifosfamide (5 g m–2; day 15)
CEB carboplatin (400 mg m–3 (GFR-corrected); day 1) 7 (10%)
etoposide (120 mg m–2; days 1–3)
bleomycin (30 mg; days 2, 9, 16)
Carboplatin-mono (400 mg m–2 (GFR-corrected); day 1) 6 (8%)
GFR = glomerular filtration rate.In relation to the treatment modalities, patients treated with
CT+SRRTM reported an unfulfilled wish for children more
often (31%) as compared to patients belonging to the CT (13%,
P = 0.03), SV (14%), or RPLND (7%) groups. Twenty of 87
patients (20%) scheduled to receive CT or RPLND were offered
sperm cryopreservation before treatment. Only eight of those
patients (40%) had accepted sperm-banking, two of whom were
planning in-vitro fertilization (25%). None of the infertile patients
planned to adopt children in the near future (Table 3).
Courses of pregnancies in women with testicular
cancer patients as partners
Except for one child with a low birth weight (2225 g) (CT), all
other 20 women had a normal course of pregnancy. Minor compli-
cations (bleeding and premature start of labour) were observed in
two women. Nine of 21 pregnant women (43%) chose a higher rate
of pregnancy check-up which was measured by the number of
amniocenteses (four of 21), ultrasound examinations or physician
consultations. Nineteen women had a spontaneous delivery, and in
two women a Caesarian section was carried out. The mean birth
weight and height were 3398.5 g (range 2225–4070) and 51.5 cm
(range 46–56). Three spontanous abortions were reported in the
total cohort. All abortions occurred before the 14th week of
gravidity. Concerning the health status of the offspring, there were
no major birth defects or complications during and after birth. All
children have been reported to develop normally up to a median
age of 62 months (range 1–180). Two children with congenital
defects, one with cryptorchidism and one with hip dysplasia, were
identified (Table 4).
Sexual dysfunctioning
The incidences of various types of sexual dysfunctions are listed in
Table 5. In total, 29 patients (30%) were found to have ejaculation
problems after treatment. A significantly higher incidence was
observed in patients who underwent RPLND alone (45%,
P = 0.03) or a secondary resection after chemotherapy
(CT+SRRTM = 55%, P = 0.01) as compared to patients treated
with chemotherapy alone (11%). In three of 29 patients (10%) the
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Table 2 Characteristics of 98 testicular cancer patients according to treatment modality
Treatment groups (No. of patients)
All (patients) SV RT RPLND CT CT+SRRTU
Eligible patients 98 7 (7%) 4 (4%) 13 (13%) 32 (33%) 42 (43%)
Median current age (years) 38.5 39 47 40 37 40
Range (25–55) (30–52) (37–53) (30–50) (27–53) (25–55)
Months from diagnosis 120 97 164 169 110 141.5
Range (34–307) (55–259) (109–230) (34–238) (73–171) (43–307)
Median age at diagnosis (years) 28 32 32 28 29 27
Range (17–44) (23–44) (29–40) (19–43) (19–44) (17–41)
Histology
Seminoma 20 (100%) 2 (29%) 4 (100%) 3 (23%) 5 (16%) 6 (14%)
Non-seminoma 78 (98%) 5 (71%) – 10 (77%) 27 (84%) 36 (86%)
Stage (according to Lugano classification)
I 24 (92%) 7 (100%) 4 (100%) 9 (69%) – 4 (10%)
II 50 (91%) – – 3 (23%) 18 (56%) 29 (69%)
III 17 (89%) – – – 10 (31%) 7 (17%)
(Ne) 7 (100%) – – 1 (8%) 4 (13%) 2 (5%)
RPLND, retroperitoneal lymph node dissection; CT+SRRTU, chemotherapy and retroperitoneal lymph node resection (mostly lumpectomy); CT, chemotherapy;
RT, radiotherapy; SV, surveillance; NE, not evaluable.
Table 3 Fertility status in testicular cancer patients
Treatment groups (No. of patients)
All (patients) SV RTa RPLND CT CT+SRRTU P-value
Fathered children before treatment 39 (40%) 0 4 (100%) 8 (62%) 14 (44%) 13 (31%) 0.03
Fathered children after treatment 21 (21%) 2 (29%) 2 (50%) 2 (15%) 7 (22%) 8 (19%) 0.90
0.03
Unfulfilled wish for children 19 (19%) 0 0 1 (7%) 5 (16%) 13 (31%) 0.10
Fertility testing 15 (15%) 0 0 1 (7%) 5 (16%) 9 (21%) 0.42
Plan to adopt children 0 0 0 0 0 0 –
Cryopreservation offered before treatment 20 (20%) 0 0 1 12 (38%) 7 (17%) 0.14
Cryopreservation done 8 (8%) 0 0 0 3 (9%) 5 (12%) 0.66
Plan in vitro fertilization 2 (2%) 0 0 0 1 (3%) 1 (2%) 1.0
a This subgroup of patients was not considered for statistical analysis comparing treatment groups. RPLND, retroperitoneal lymph node dissection; CT+SRRTU,
chemotherapy and retroperitoneal lymph node resection (mostly lumpectomy); CT, chemotherapy; RT, radiotherapy; SV, surveillance; NE, not evaluable.ejaculatory function recovered between 1 and 3 years after
treatment. Sixteen patients reported a decrease in the quantity of
semen fluid production: six patients reported slight and ten
patients severe reductions. The reduction of semen fluid quantity
appears to be related to RPLND (31%, P = 0.06).
Eight per cent of patients reported dissatisfaction with their
sexual life before the diagnosis of cancer. Two patients reported
loss of sexual drive (2%) and one patient reported a reduced
erectile potential (1%). A score to self-adjust the intensity of
sexual life (including the frequency of sexual intercourse and the
intensity of orgasms) showed no difference before and after treat-
ment for all patients, with a mean score of 2.3 (P = 0.51). As
expected, the score significantly decreased during treatment (data
not shown), but recovered almost completely after treatment, with
no differences between treatment groups. ‘Loss of sexual drive’,
‘reduced erectile potential’ and ‘dissatisfaction with sexual life’
were observed more frequently after treatment compared to
pretreatment status but this was not statistically significant. The
highest incidences regarding those disorders was seen in patients
receiving CT+SRRTM (not significant). Age and duration of
follow-up did not influence the incidence of sexual disorders.
DISCUSSION
Despite a reasonable number of retrospective studies investigating
the influence of treatment on sexual function, the question remains
open whether and in what degree testicular cancer patients are at
risk for sexual morbidity (Rieker et al, 1985, 1989; Schover and
Eschenbach, 1985; Schover et al, 1986; Moynihan, 1987; Gritz
et al, 1989; Stoter et al, 1989; Tinkler et al, 1992; Aass et al, 1993;
Arai et al, 1997; Jonker-Pool et al, 1997). The available data vary
widely and a correlation to different treatment modalities is
lacking in most studies. Furthermore, the comparison of different
studies is difficult due to differences in irradiation procedures,
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Table 4 Pregnancies in female partners of patients treated for testicular cancer
Treatment groups (No. of patients)
All (= 21) SV RT RPLND CT CT+SRRTU
Increased prevention check up 9 (43%) 1 (33%) 1 (50%) 1 (50%) 2 (29%) 4 (50%)
Amniocentesis 4 (19%) 1 (33%) 1 (50%) – – 2 (25%)
Course of pregnancy
Normal 19 (90%) 1 (66%) 2 (100%) 2 (100%) 7 (100%) 7 (88%)
Complications 2 (10%) 1 (33%) – – – 1 (13%)
Miscarriage after treatment 3 (3%) – 1 (25%) – 1 (3%) 1 (2%)
Delivery
Spontanous 16 (76%) 2 (66%) 2 (100%) 2 (100%) 5 (71%) 5 (63%)
Caesarian section 2 (10%) – – – 2 (29%) –
Children
Mean birth weight 3398.5 3000 (2400–3600) 3700 (3700–3700) 3500 (3500–3500) 3425 (2225–4070) 3431 (2950–3870)
Mean birth height 51.5 (46–56) 49.5 (46–53) 53.0 (53–53) 54.0 (52–56) 51.2 (50–53) 51.4 (49–56)
RPLND, retroperitoneal lymph node dissection; CT+SRRTU, chemotherapy and retroperitoneal lymph node resection (mostly lumpectomy); CT, chemotherapy;
RT, radiotherapy; SV, surveillance; NE, not evaluable.
Table 5 Sexual dysfunction in men with testicular cancer
Treatment groups (No. of patients)
All (patients) SV RTa RPLND CT CT+SRRTU P-value
0.03 0.01
Inability to ejaculate 29 (30%) – – 5 (45%) 3 (9%) 21 (55%) <0.001
Reduced semen volume 
Total  16 (16%) – – 4 (31%) 5 (16%) 7 (17%) 0.38
Slightly 6 – – 1 (8%) 4 (13%) 1 (2%) 0.27
0.06
Severe 10 – – 3 (23%) 1 (3%) 6 (14%) 0.12
Dissatisfaction with sexual life
Pretreatment 8 (8%) 1 (14%) – 1 (8%) 2 (6%) 7 (17%) 0.60
Post-treatment 13 (13%) 1 (14%) – 2 (15%) 3 (9%) 4 (10%) 0.92
Loss of sexual drive
Pretreatment 2 (2%) – – – 2 (6%) – 0.28
Post-treatment 7 (7%) – – – 1 (3%) 6 (14%) 0.18
Reduced erectile potential
Pretreatment 1 (1%) – – – – 1 (2%) 1.0
Post-treatment 9 (9%) – – – 3 (9%) 6 (14%) 0.40
a This subgroup of patients was not considered for statistical analysis comparing treatment groups. RPLND, retroperitoneal lymph node dissection; CT+SRRTU,
chemotherapy and retroperitoneal lymph node resection (mostly lumpectomy); CT, chemotherapy; RT, radiotherapy; SV, surveillance; NE, not evaluable.chemotherapy regimens, composition of the cohort of patients and
in the aims of each study. We report nearly 100 patients who
underwent different treatment modalities for testicular germ cell
tumour between 1970 and 1993. This descriptive study provides
data about sexual function, fertility status/distress and the adaptive
behavioural responses, and reports on the courses and outcome of
pregnancies after treatment.
For testicular cancer survivors the highest child-bearing poten-
tial after treatment has been reported in seminoma patients who
were treated with radiation therapy alone. The lowest rates were
observed in patients who had undergone retroperitoneal surgery
plus cisplatin-based chemotherapy (Rieker et al, 1985, 1989;
Schover and Eschenbach, 1985; Petersen et al, 1994; Arai et al,
1997). In this series patients receiving CT+SRRTM reported child-
lessness more frequently compared to patients treated with CT
alone. Despite the observation of a comparable decrease in subjec-
tive sexual aspects (libido, orgasm, satisfaction) in both treatment
groups, the combined treatment resulted in a higher fertility
distress. This is in accordance with a report by Arai et al (1997)
who reported a 21% difference between both groups concerning
desire for children (68% vs 47%). Compared to the frequency of
unintentional childlessness in the German population (about 17%),
only patients receiving both chemotherapy and retroperitoneal
surgery appear to have a higher incidence of an unfulfilled wish for
children, whereas for all other treatment groups the incidence was
lower (Bruckert, 1991).
Today, sperm-banking may be beneficial even for patients who
are subfertile at the time of diagnosis, because the techniques of
sperm preservation and in-vitro fertilization rapidly advances.
Sperm-banking awareness is one of several possible fertility
adjustment responses, besides adoption awareness, fertility testing
and trying to father children and fertility distress (Rieker et al,
1990). The psychological aspects of infertility, its psychosomatic
components on health and sexuality have been described
elsewhere (Burns, 1987). In the current investigation, 20 of
87 (23%) patients who underwent CT or RPLND reported that
cryopreservation had been offered to them. Forty per cent of
them had performed sperm-banking and two of those patients were
planning in vitro fertilization. Although sperm-banking awareness
was somewhat lower than described by Rieker et al (1990), the
number of men who had performed sperm-banking was in the
same range. In our investigation, none of the patients were
planning to adopt children in the near future. In the above
mentioned study, 21% of men considered adoption and 3% had
adopted a child.
Although our cohort of patients with 21 born children is too
small for definitive conclusions, we did not observe an elevated
rate of complications during pregnancies in the partners of our
testicular cancer patients. The rate of pregnancy check-up
appeared to be higher as compared to the general population. Four
of 21 women underwent amniocentesis (19%) and approximately
40% consulted their physician earlier than is the norm. Altogether,
three of 26 pregnancies were miscarriages. No adverse pregnancy
outcome defined as fetal or neonatal death or severe congenital
malformation was observed, with the exception of the premature
birth of a live-born infant weighing 2225 g. There are only limited
data about the pregnancy outcome of partners of male cancer
survivors (Brenner et al, 1985; Stoter et al, 1989; Senturia and
Peckham, 1990; Byrne and Mulvihill, 1991). Another investiga-
tion regarding children fathered after the remaining gonad had
been exposed to chemotherapy had also found no evidence of an
increased risk of congenital malformations compared to matched
controls (Dodds et al, 1993). A recent investigation showed no
significantly increased risk of non-hereditary cancer among the
offspring of survivors of cancer in childhood (Sankila et al, 1998).
No pregnancies occurred during the actual cancer treatment period;
patients were advised to perform birth control during therapy.
It has been demonstrated that testicular cancer can affect sexual
function (Jonker-Pool et al, 1997). The incidences of subjective
aspects, like ‘loss of libido’, ‘erectile dysfunction’ and ‘reduced
satisfaction with sexual life’ were 7%, 9% and 13% respectively.
Data available from the literature ranged from 4% up to 38% in
different reports (Rieker et al, 1985; Schover and Eschenbach,
1985; Moynihan, 1987; Schover, 1987; Fossa et al, 1988; Gritz
et al, 1989; Jonker-Pool et al, 1997). It has been suggested that
sexual dysfunctions are related to the intensity and the modality of
the treatment. A low incidence of sexual dysfunction was observed
in surveillance patients or in seminoma patients undergoing
irradiation (Rieker et al, 1985; Schover and Eschenbach, 1985;
Jonker-Pool et al, 1997). Patients who underwent chemotherapy
(± SRRTM) appeared to be at the highest risk for sexual dysfunc-
tion (Rieker et al, 1985; Arai et al, 1997; Jonker-Pool et al, 1997).
With the exception of absence of ejaculation, no major difference
has been reported between the CT and CT+SRRTM therapies
(Arai et al, 1997; Jonker-Pool et al, 1997; van Basten et al, 1997b;
own series). According to expectations, absence of antegrade
ejaculation was reported by 45% and 55% (P = 0.03 and P = 0.01)
of our patients undergoing RPLND or CT+SRRTM. Possible
damage is related to the extent of the retroperitoneal surgical
approach (Nijman et al, 1987; Jones et al, 1993). All of our
patients with primary RPLND had stage II disease and underwent
unilateral RPLND either as a radical procedure (before 1992)
or as a modified RPLND (after 1992). Secondary resection of
residual masses after chemotherapy was usually performed as a
lumpectomy (Hartmann et al, 1997a, 1997b).
Absence of ejaculation was reported by three patients treated
with CT alone (9%). Chemotherapy may affect the hormonal,
vascular and nervous systems (van Basten et al, 1995, 1997a).
All of these systems are important for sexual function and their
disturbance may thus cause ejaculatory problems. This rare obser-
vation was reported previously by another investigator in 7% of
chemotherapy-treated patients (Arai et al, 1997). A decreased
erectile potential was observed in 9% of our patients, which
is within the range of other investigations (Arai et al, 1997;
Jonker-Pool et al, 1997). A higher incidence has been reported
in patients undergoing radiation therapy (15–48%) (Arai et al,
1997; Jonker-Pool et al, 1997; van Basten et al, 1997a).
In conclusion, long-lasting sexual problems after therapy for
testicular cancer are present in approximately one-fifth of patients
undergoing treatment for testicular germ cell tumour. On the other
hand, the majority of patients have not reported infertility or sexual
dysfunction-related symptoms. Ejaculation disturbances were
found in a large number of patients undergoing RPLND. The rela-
tive risk for infertility appears to be elevated for patients treated
with the combination of CT+SRRTM leading to a definitve
number of infertile men. The courses of pregnancies in partners of
testicular cancer survivors did not differ from those of the general
population and no major birth defects or serious chronic diseases
were detectable in any of 21 children. This finding confirms other
studies in long-term survivors of cancer treatment which revealed
no increased risk for congenital abnormalities or late effects in
the offspring.
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